Raymond James Reiterates Strong Buy Rating on Inflarx NV (IFRX), PT $13

Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $13.00 price target on Inflarx NV (NASDAQ: IFRX).

The analyst comments "We are updating our model to reflect 1Q25 earnings, please refer to our 1Q25 earnings update here for our takeaways from the quarter. Our Strong Buy rating and $13 price target remains unchanged, driven primarily by our positive outlook on IFRX’s upcoming readouts for vilobelimab (pyoderma gangrenosum, see our note on the prior PG clinical dataset here) and C5aR inhibitor, INF904 (see our note here for more details on this drug) based on the validated therapeutic activity of vilobelimab and early-stage derisking of the straightforward wound closure primary endpoint in PG. 1Q25 EPS Summary. R&D expense of €8.0M was below €8.7M consensus. EPS of (€0.13) was above consensus (€0.21). Cash and equivalents of €65.7M are expected to provide runway into 2027."

For an analyst ratings summary and ratings history on Inflarx NV click here. For more ratings news on Inflarx NV click here.

Shares of Inflarx NV closed at $1.67 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August